OLD National Bancorp IN Has $2.36 Million Stake in Amgen Inc. (NASDAQ:AMGN)

OLD National Bancorp IN trimmed its stake in Amgen Inc. (NASDAQ:AMGN) by 2.0% in the fourth quarter, HoldingsChannel.com reports. The firm owned 8,187 shares of the medical research company’s stock after selling 167 shares during the period. OLD National Bancorp IN’s holdings in Amgen were worth $2,358,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of AMGN. Commerzbank Aktiengesellschaft FI grew its holdings in Amgen by 0.9% during the 4th quarter. Commerzbank Aktiengesellschaft FI now owns 43,759 shares of the medical research company’s stock worth $12,603,000 after acquiring an additional 407 shares during the period. Cetera Trust Company N.A acquired a new stake in Amgen during the 4th quarter worth about $2,963,000. Nikulski Financial Inc. grew its holdings in Amgen by 35.7% during the 4th quarter. Nikulski Financial Inc. now owns 2,710 shares of the medical research company’s stock worth $781,000 after acquiring an additional 713 shares during the period. Handelsbanken Fonder AB grew its holdings in Amgen by 1.1% during the 4th quarter. Handelsbanken Fonder AB now owns 367,586 shares of the medical research company’s stock worth $105,872,000 after acquiring an additional 3,830 shares during the period. Finally, CWM LLC grew its holdings in Amgen by 1.3% during the 4th quarter. CWM LLC now owns 122,898 shares of the medical research company’s stock worth $35,397,000 after acquiring an additional 1,627 shares during the period. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Price Performance

Shares of NASDAQ AMGN opened at $271.91 on Tuesday. Amgen Inc. has a twelve month low of $211.71 and a twelve month high of $329.72. The stock’s 50 day moving average price is $276.45 and its 200-day moving average price is $281.56. The company has a market capitalization of $145.85 billion, a PE ratio of 21.77, a PEG ratio of 2.50 and a beta of 0.58. The company has a quick ratio of 1.13, a current ratio of 1.65 and a debt-to-equity ratio of 10.14.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, February 6th. The medical research company reported $4.71 earnings per share for the quarter, topping analysts’ consensus estimates of $4.66 by $0.05. Amgen had a return on equity of 154.27% and a net margin of 23.83%. The firm had revenue of $8.20 billion for the quarter, compared to the consensus estimate of $8.13 billion. During the same quarter in the previous year, the business earned $4.09 EPS. The company’s revenue was up 19.8% compared to the same quarter last year. On average, equities analysts anticipate that Amgen Inc. will post 19.45 EPS for the current year.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be paid a $2.25 dividend. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $9.00 annualized dividend and a yield of 3.31%. Amgen’s payout ratio is 72.06%.

Analysts Set New Price Targets

AMGN has been the subject of a number of research analyst reports. The Goldman Sachs Group boosted their target price on Amgen from $313.00 to $350.00 and gave the company a “buy” rating in a research report on Wednesday, February 7th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $329.00 target price on shares of Amgen in a research report on Wednesday, April 3rd. UBS Group decreased their target price on Amgen from $314.00 to $284.00 and set a “neutral” rating for the company in a research report on Wednesday, April 17th. Raymond James initiated coverage on Amgen in a research report on Thursday, March 28th. They issued a “market perform” rating for the company. Finally, Truist Financial reaffirmed a “buy” rating and issued a $320.00 target price on shares of Amgen in a research report on Friday, April 12th. Ten research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $296.95.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.